Abstract
There is a growing interest focusing on the inflammatory response caused by essential hypertension. Inflammatory mechanisms play an important role in the pathogenesis and progression of cardiovascular disease. Recent studies have shown that tissue expression and plasma concentrations of several inflammatory markers and mediators are associated with increased risk of hypertension. These molecules include C-reactive protein, adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and chemokines. The evaluation of these markers may influence the specific pharmacologic responses and the clinical outcome of the patients with essential hypertension. Moreover, therapeutic approaches targeted to lower blood pressure and suppress inflammatory response may have additional clinical benefits. However, further randomized studies are required to determine the potential favorable effects of suppression of inflammation in the management of arterial hypertension.
Keywords: Hypertension, inflammation, markers, therapeutic approaches
Current Vascular Pharmacology
Title: Inflammatory Markers in Essential Hypertension: Potential Clinical Implications
Volume: 8 Issue: 4
Author(s): Elli Stefanadi, Dimitris Tousoulis, Emmanuel S. Androulakis, Nikolaos Papageorgiou, Marietta Charakida, Gerasimos Siasos, Costas Tsioufis and Christodoulos Stefanadis
Affiliation:
Keywords: Hypertension, inflammation, markers, therapeutic approaches
Abstract: There is a growing interest focusing on the inflammatory response caused by essential hypertension. Inflammatory mechanisms play an important role in the pathogenesis and progression of cardiovascular disease. Recent studies have shown that tissue expression and plasma concentrations of several inflammatory markers and mediators are associated with increased risk of hypertension. These molecules include C-reactive protein, adhesion molecules, such as vascular cell adhesion molecule-1, intercellular adhesion molecule-1 and chemokines. The evaluation of these markers may influence the specific pharmacologic responses and the clinical outcome of the patients with essential hypertension. Moreover, therapeutic approaches targeted to lower blood pressure and suppress inflammatory response may have additional clinical benefits. However, further randomized studies are required to determine the potential favorable effects of suppression of inflammation in the management of arterial hypertension.
Export Options
About this article
Cite this article as:
Stefanadi Elli, Tousoulis Dimitris, S. Androulakis Emmanuel, Papageorgiou Nikolaos, Charakida Marietta, Siasos Gerasimos, Tsioufis Costas and Stefanadis Christodoulos, Inflammatory Markers in Essential Hypertension: Potential Clinical Implications, Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330870
DOI https://dx.doi.org/10.2174/157016110791330870 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Vitamin D and the Metabolic Syndrome
Current Vascular Pharmacology Targeted Therapies in Hepatocellular Carcinoma
Current Medicinal Chemistry Theory and Application of Microdialysis in Pharmacokinetic Studies
Current Drug Metabolism Cardio-Hepatic Metabolic Derangements and Valproic Acid
Current Clinical Pharmacology Apoptosis Modulated by Oxidative Stress and Inflammation During Obstructive Nephropathy
Inflammation & Allergy - Drug Targets (Discontinued) Cardiovascular Risk in Rheumatoid Arthritis and Mechanistic Links: From Pathophysiology to Treatment
Current Vascular Pharmacology Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Current Pharmaceutical Design Modulators of the Vascular Endothelin Receptor in Blood Pressure Regulation and Hypertension
Current Molecular Pharmacology Editorial (Should Chronic Kidney Disease be Considered as a Coronary Heart Disease Equivalent?)
Current Vascular Pharmacology Effect of Soy Isoflavone Supplementation on Endothelial Dysfunction and Oxidative Stress in Equol-Producing Postmenopausal Women
Endocrine, Metabolic & Immune Disorders - Drug Targets Neutrophil Gelatinase-Associated Lipocalin (NGAL) and Endothelial Progenitor Cells (EPCs) Evaluation in Aortic Aneurysm Repair
Current Vascular Pharmacology Hypertension - Current Natural Strategies to Lower Blood Pressure
Current Pharmaceutical Design Design and Optimization of Chronotherapeutic Dosage Form for the Treatment of Angina Pectoris
Drug Delivery Letters Formulation of Gastric Floating System Using Bio-Sourced Terminalia Catappa Gum and in vivo Evaluation
Current Drug Delivery Novel Drug Targets for the Treatment of Cardiac Diseases
Current Pharmacogenomics and Personalized Medicine Molecular Targets and Angiogenesis in Renal Cell Carcinoma, A Multitarget Approach: Mini Review
Current Drug Targets Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design Endocannabinoids and their Involvement in the Neurovascular System
Current Neurovascular Research Ouabain Antagonists as Antihypertensive Agents
Current Pharmaceutical Design Immunomodulation in Inflammatory Neuropathies: Rationale and Safety
Current Drug Safety